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Unraveling the therapeutic potential of human
embryonic stem cells (hESC) requires tools to modify
their genome. We have engineered the PiggyBac
transposable element to create an efficient system
for gene delivery in hESCs. This redesigned system,
named ‘‘ePiggyBac,’’ can deliver up to 18 Kb inserts,
and transgene expression is observed in almost 90%
of hES cells. ePiggyBac transposons can also carry
insulators, inducible expression cassettes, and
short hairpin RNAs for gain- and loss-of-function
approaches. In hES cells, ePiggyBac’s efficiency is
superior to that of viral vectors and previously
described transposons, including other PiggyBac-
based systems. In addition, ePiggyBac transgenes
can be removed from the hESC genome without
leaving any mutation. We used this system to direct
hESC differentiation toward a neuronal phenotype.
We then removed the transposons to obtain trans-
gene-free neuronal precursors and neurons. The
ability to create fully reversible genetic modifications
represents an important step toward clinical applica-
tions of hESCs.
INTRODUCTION
Human pluripotent stem cells hold remarkable potential for
regenerative medicine and drug screens. They also provide a
unique opportunity to improve our understanding of human
development and diseases. However, a difficulty in generating
transgenic hESC lines and use of reporter systems or gain-
and loss-of-function approaches still limit our ability to fully
unravel their potential.
Currently, gene transfer into hESCs is mostly based on the use
of viral vectors. These vectors can mediate transgene expres-
sion in 20%–80%of human ES cells (Ben-Dor et al., 2006; Pfeifer
et al., 2002), but their cargo size is restricted to about 5 Kb and
their insert is often limited to one expression cassette. Nonviral
systems that use the Sleeping Beauty transposon are also
restricted to a cargo size of 5–6 Kb (Wilber et al., 2007). These
characteristics limit the use of selectable markers, inducible
cassettes, insulators, and large regulatory sequences often332 Cell Stem Cell 5, 332–342, September 4, 2009 ª2009 Elsevier Inrequired to restrict transgene expression to specific cell types.
Baculoviruses can deliver larger cargo to hESC (Zeng et al.,
2007), but the long-term effect of adeno-associated rep protein
expression could lead to undesirable effects (McCarty et al.,
2004). In principle, plasmids and bacterial artificial chromo-
somes (BACs) can be used when large promoters are required,
but stable integration of these vectors in the hESC genome is
relatively inefficient and plasmid-borne transgenes are subject
to silencing (Braam et al., 2008). In addition, BACs usually carry
several intact genes in addition to the engineered locus;
therefore, their integration in the genome leads to gene multipli-
cations. This may have important consequences when the
supernumerary genes have regulatory functions.
Regardless of efficiency, gene transfer technologies currently
available in hESCs such as viral vectors, Sleeping Beauty trans-
posons, or PhiC31 integrase (Thyagarajan et al., 2008) mediate
irreversible genome modifications. This constitutes a major
barrier to the clinic because the presence of exogenous inserts
in certain loci may lead to higher predisposition toward tumori-
genesis or uncontrolled cellular behavior.
In the present study, we designed a gene transfer system for
reversible integration of large multigene inserts in hESCs. We
chose the PiggyBac transposon (Cary et al., 1989; Fraser et al.,
1995, 1996) as a starting point for our design because this gene
delivery system is nonviral and can carry cargo sizes of up to
14.3 Kb. It also exhibits higher activity than other transposons
in mammalian models (Cadinanos and Bradley, 2007; Ding
et al., 2005; Wilson et al., 2007). Importantly, PiggyBac does
not leave mutations upon remobilization in HEK293 cells (Wilson
et al., 2007), suggesting that it could be used for fully reversible
transgene delivery in hESC. This property was recently used to
generate transgene-free induced pluripotent cells in the mouse
(Yusa et al., 2009; Kaji et al., 2009; Woltjen et al., 2009).
RESULTS
Engineering a PiggyBac Transposon for Efficient Gene
Transfer Efficiency in hESCs
The original 2.4 Kb PiggyBac element includes the PiggyBac
transposase, which mediates gene transfer, and a transposon
flanked by 50- and 30-terminal repeats necessary for transposi-
tion (Cary et al., 1989; Fraser et al., 1995, 1996). For gene delivery
experiments, the PiggyBac system can be divided into a donor
plasmid that contains the transposon and a helper plasmid
that expresses the transposase (Cary et al., 1989; Wilson et al.,c.
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ePiggyBac2007). To test the ability of PiggyBac to mediate gene transfer in
hESCs, we first designed basic EGFP- or RFP-expressing donor
plasmids (Figure 1A) that contain a 50-terminal repeat (50TR) of
313 bp and a 30-terminal repeat (30TR) of 235 bp. These two
minimal sequences are necessary and sufficient for transposi-
tion (Li et al., 2005). Our initial attempts used a helper plasmid
expressing the original insect PiggyBac transposase. Donor and
helper plasmids were cotransfected in the hESC line RUES2
and genome integration efficiency was assessed by counting
the number of EGFP-positive colonies 7 days after transfection.
In control experiments, the donor plasmid was transfected in
the absence of transposase in circular or linearized forms to
compare the efficiency of PiggyBac-mediated gene delivery
with that of random integration of plasmid DNA.
The original PiggyBac transposase is active in hESCs and
mediates higher genome integration efficiency than random inte-
gration of a linearized plasmid (Figure 1B), but transposition effi-
ciency remains low (10.4 ± 6.04 EGFP-positive colonies per 2000
transfected cells). This prompted us to engineer the PiggyBac
transposable element to optimize its activity in hESCs. Because
PiggyBac was originally isolated from an insect, we introduced
silent mutations to generate a codon usage similar to that of
humans. A piggyBac transposase that uses rodent codon usage
has already been described (Cadinanos and Bradley, 2007), but
human splice site prediction algorithms (Brunak et al., 1991)
detect the presence of cryptic splicing sites in that synthetic
transgene. This prompted us to design an improved transposase
cDNA for use in human embryonic stem cells (Figure S1 available
online). The codon-humanized PiggyBac transposase increased
genome integration efficiency by 10-fold: 5%of transfected cells
stably integrated the transgeneandgave rise togreenfluorescent
colonies (Figure 1B). This rate of transgenesis is similar to that of
other transposable systems for inserts of this size (Wilber et al.,
2007).
We next engineered the transposon’s 50- and 30-terminal
repeats to further improve gene delivery. The terminal repeats
were modified by random PCR-mediated mutagenesis. Twenty
different mutants were isolated for each terminal repeat and
used to replace their wild-type counterparts in the original donor
plasmid (Figure 1A). Mutated donor plasmids were then cotrans-
fected with a helper plasmid containing the codon-humanized
transposase cDNA. A 59% increase in transposition efficiency
(Figure 1C) was observed in a 50TR mutant carrying T53C and
C136T substitutions (Figure S2). The improved PiggyBac
system, comprising the codon-humanized transposase and
the T53C/C136T mutant 50TR, was named ePiggyBac for
‘‘enhanced PiggyBac.’’
To ensure that ePiggyBac could be widely used in hESC
research, we performed gene delivery experiments in hESC
and nonhuman primate ESC lines. ePiggyBac could efficiently
transfer EGFP- or RFP-expressing transgenes in different
hESC lines (Figure 1D). We also found that ePiggyBac-mediated
gene delivery does not alter the hESC karyotype (Figure S3) or
the ability of hESCs to express pluripotency markers, form
embryoid bodies, and differentiate into all three germ layers
(Figures S4 and S5). In addition, gene transfer efficiency re-
mained high in nonhuman primate ESCs (Figure 1D), indicating
that ePiggyBac can be used as a generic gene delivery system
in primate ESCs.CeWe also investigated whether silencing, which is known to
occasionally occur in plasmid- and viral-based transgenes in
hESCs, affects ePiggyBac-mediated transgenesis. We gener-
ated two single-transgenic RUES2 lines expressing either
EGFP or RFP and a double transgenic RUES2 line expressing
both EGFPandRFP. These lineswerepassaged 25 timeswithout
selection and the proportion of cells that had lost transgene
expression was then quantified by FACS analysis. Results
showed that in these three independent clones, the proportion
of nonfluorescent events detected by flow cytometry was
between 0.1% and 0.2% (Figure 1E), indicating that silencing of
ePiggyBac transposons is rare, possibly more so than silencing
of plasmid- and virus-based transgenes.
One of the most important advantages of PiggyBac over other
gene delivery systems lies in its ability to carry large cargo size
(Ding et al., 2005). To investigate ePiggyBac’s ability to integrate
large DNA constructs in the hESC genome, we added inserts of
increasing size to our basic transposon (Figure 1F). We found
that, although transposition efficiency decreased significantly
for inserts larger than 12 Kb, ePiggyBac could deliver inserts of
up to 18 Kb in size to the hESC genome, which is larger than
the insert size delivered by the original PiggyBac system
(Figure 1F) or the maximum 14.3 Kb insert size previously
reported for mouse embryos (Fraser et al., 1995).
We next tested whether ePiggyBac could deliver large inserts
containing several components such as expression cassettes,
insulator sequences, and plasmid rescue systems. We created
a 12 Kb transposable insert containing an origin of replication
for plasmid rescue, a constitutively expressed neomycin-phos-
photransferase cassette and a reporter construct where EGFP
expression is driven by the human Oct4 promoter (Figure 1G;
Gerrard et al., 2005). We included a chicken HS4 insulator (Recil-
las-Targa et al., 2002) to prevent the constitutively expressed
neomycin cassette from interfering with the hOct4-EGFP
reporter,which should label only undifferentiated hESCs (Gerrard
et al., 2005). After gene delivery, 7 days of neomycin selection
were sufficient to select EGFP-positive colonies that could be
expanded to establish an hOct4-EGFP RUES2 cell line. To test
the specificity of EGFP labeling, we compared levels of fluores-
cence in cells cultured in nondifferentiating conditions to those
in cells maintained in differentiating conditions (Figure 1H).
Live-cell imaging showed that EGFP labeling is lost in cells main-
tained in differentiating conditions and in 18-day-old embryoid
bodies. In addition, coimmunostaining showed that the decrease
in EGFP expression is consistent with the decrease in endoge-
nous Oct4 protein expression (Figures 1I and 1J). These experi-
ments indicate that ePiggyBac can integrate large multicompo-
nent inserts into the hESC genome without altering their
functionality.
Finally, we systematically altered gene-delivery parameters
to define conditions that would further increase gene-delivery
efficiency and complement our molecular modifications to the
transposase and transposon. We found that expressing the
transposase from the CAG promoter, by means of 6 mg of DNA
per 1.5 3 105 cells, a transposase/transposon ratio of 1:2, and
transfection solution L instead of V (Siemen et al., 2005) led to
a dramatic increase in transgenesis efficiency. By using ePiggy-
Bac under these conditions, we commonly obtain transgene
expression in almost 90% (Figure 1K) of hESC colonies for all Stem Cell 5, 332–342, September 4, 2009 ª2009 Elsevier Inc. 333
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Figure 1. An Engineered PiggyBac Transposable Element for Efficient Gene Delivery in Human and Nonhuman Primate ESCs
(A) Schematic representation of the basic EGFP- or RFP-expressing transposable transgenes. Purple triangles represent 50- and 30-terminal repeats required for
transposition.
(B) RUES2 cells were transfected with a circular plasmid containing the EGFP-expressing transposon (neg.), a linearized plasmid containing the EGFP-expressing
transposon (lin.), or a circular plasmid containing the transposon together with a helper plasmid expressing the original PiggyBac transposase (wt) or the codon-
humanized PiggyBac transposase (co). Two thousand cells were plated and cultured for 7 days before numbers of fluorescent colonies were determined. The
codon-humanized transposase mediated significantly higher gene transfer efficiency (p < 0.01 co versus wt, n = 3 independent repeats).
(C) To improve gene-transfer efficiency, 20 50TR mutants were generated by random PCR mutagenesis. Mutant number 16, which carries T53C and C136T
mutations, led to a significant (p < 0.01 versus control, n = 3 independent repeats) increase in gene delivery.
(D) The engineered PiggyBac system composed of the codon-humanized transposase and the T53C/C136Tmutant 50TRmediates efficient gene delivery in hESC
lines RUES2, RUES1, H1, HUES10, and BGN1 as well as Macacca ESC lines.
(E) FACS analysis of three independent transgenic RUES2 clones (RUES2-EGFP, RUES2-RFP, RUES2-EGFP/RFP) after 25 passages without selection indicate
that ePiggyBac transposon silencing is minimal.
(F) Inserts of increasing size were added to the basic PGK-EGFP transposon and number of fluorescent colonies were counted 7 days after gene delivery
by ePiggyBac (solid bars) or original PiggyBac (open bars). ePiggyBac was able to deliver transgenes of up to 18 Kb with significantly higher efficiency
(p < 0.001 ePiggyBac versus original PiggyBac, n = 3 studies).
(G) Schematic representation of the hOct4-EGFP transposable element. The 12 Kb transgene includes a neomycin selection cassette (Neo), an HS4 chicken
insulator, and a 4 Kb human Oct4 promoter driving EGFP expression (pA, poly(A) signal).
(H) Time-lapse imaging of single neomycin-resistant colonies kept undifferentiated in conditioned medium (CM) or differentiated in nonconditioned medium (No
CM). Fluorescence levels remain high in undifferentiated cells while they decrease with time as differentiation progresses. 18-day embryoid bodies (EB) have lost
most of the hOct4-EGFP labeling.334 Cell Stem Cell 5, 332–342, September 4, 2009 ª2009 Elsevier Inc.
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ePiggyBac3 Kb transposon (72.1% ± 8.3% for an 18 Kb transposon), which
is higher than gene delivery efficiencies reported for viral vectors
(Ben-Dor et al., 2006; Pfeifer et al., 2002). We currently use
ePiggyBac routinely and regularly conduct karyotypic analyses
to verify that our ePiggyBac transgenic cell lines remain free of
chromosomal abnormalities. Analysis of more than 200 meta-
phases in various cell lines at passage numbers ranging from
15 to 55 has so far not revealed any chromosomal abnormalities.
This indicates that ePiggyBac transgenesis does not causemore
chromosome instability in hESCs than other gene-delivery
methods. SplinkTA PCR analyses of 70 samples indicated that
transgenic hESCs typically carried 1–12 copies when 2–3 mg of
the transposase-expressing plasmid is delivered to the cells
(Figure 1L). Interestingly, changing the amount of transposase-
expressing plasmid allows control over the number of transpo-
sons integrated in the hESC genome (Figure 1L).
Interestingly, we have noticed that in mouse ES cells, around
90% of colonies also exhibit stable transgene expression (not
shown). For comparison, Cadinanos andBradley (2007) reported
that transfection of 107 AB2.2 mouse ES cells with a mouse
codon-optimized PiggyBac transposase gave rise to only about
1000 transgenic colonies. Therefore, it appears that the combi-
nation of transposase cDNA and terminal repeat modifications
that constitute ePiggyBac are not merely incremental improve-
ments. In ES cells, ePiggyBac’s efficiency is not only superior
to that of viral vectors, it is also largely superior to that of previ-
ously described transposons, including other PiggyBac-based
systems (Cadinanos and Bradley, 2007; Woltjen et al., 2009;
Kaji et al., 2009). In addition, the efficiency of ePiggyBac is
conserved between human, nonhuman primate, and rodent
ES cells.
ePiggyBac Retains Basic PiggyBac Characteristics
To determine whether gene transfer was the result of a transpo-
sition event, sites of integration were isolated via a plasmid
rescue strategy (Figure 2A), sequenced, and analyzed by BLAST
search of the Ensembl database. Analysis of 62 ePiggyBac inte-
gration sites revealed no obvious consensus sequence other
than the TTAA tetranucleotide sequence (Figure 2B) previously
shown to be required for PiggyBac transposition (Cadinanos
and Bradley, 2007; Cary et al., 1989; Ding et al., 2005; Fraser
et al., 1995, 1996; Li et al., 2005;Wilson et al., 2007). A nucleotide
frequency plot (Figure 2C) also revealed a preference for AT-rich
regions around the core TTAA sequence. Sequence analyses
showed that ePiggyBac integrations occurred in all chromo-
somes of the female hESC line RUES2 (Figure 2D). Interestingly,
72% of integrations occurred within 10 Kb of a known transcrip-
tion start site, and 96% of integrations that took place
downstream of the transcription start site occurred in introns
(Figure 2E) as described for the original PiggyBac transposableCeelement (Ding et al., 2005; Wilson et al., 2007). These data
indicate that mutations introduced in the PiggyBac system
increased gene delivery efficiency without altering its basic prop-
erties. It is noteworthy that preferential transgene integration in
introns is also a feature of viral-based gene-delivery methods.
This indicates that alterations in gene expression patterns in
ePiggyBac transgenics are theoretically possible, as with virus-
based or other gene-delivery methods.
ePiggyBac Transgenes Can Be Removed
from the Genome
In contrast to viral vectors and PhiC31 systems, transposons
can be remobilized and moved from one locus to another by
re-expression of the transposase (Elick et al., 1996; Wilson
et al., 2007). Theoretically, re-expression of the transposase
followed by random transgene segregation upon remobilization
could enable reversion from a transgenic to a wild-type geno-
type. This approach could therefore be used for reversible
transgenesis in hESCs. However, our initial attempts to remove
transgenes from transgenic hESCs by re-expression of the
ePiggyBac transposase were largely unsuccessful. It appeared
that extensive passaging and selection procedures would be
needed to select the few hESCs where transgenes have been
segregated out of the genome. As an alternative, we investi-
gated whether transposons could be transferred from the
genome to a recipient plasmid.
Transposons are commonly transferred from a donor plasmid
to a recipient plasmid or to genomic DNA. Transfer of ePiggyBac
transposons from the genome to a plasmid would enable rever-
sions from a transgenic to a completely intact genome because
PiggyBac does not leave any mutation upon excision. However,
transposition from the genome to a recipient plasmid is an
unlikely event because plasmids are million times smaller than
the human genome, and therefore, genomic DNA is a much
more likely target for integration. To increase the probability
that ePiggyBac transposons excised from the genome are
transferred to a plasmid rather than moved to another genomic
location, we first engineered a recipient plasmid carrying 14
‘‘upstream activating sequences’’ (UAS). Next, we generated
a helper plasmid where the Gal4 DNA binding domain is fused
to the N terminus of the ePiggyBac transposase. Upon cotrans-
fection of these two vectors, the Gal4-ePiggyBac chimeric
protein binds to the UAS-carrying recipient plasmid with high
affinity, which strongly increases chances that transposons are
transferred to the recipient plasmidwithout significantly affecting
transposase activity (Maragathavally et al., 2006). To test
whether this strategy enables the removal of transposons from
the hESC genome, we created an RFP-expressing transposon
where neomycin-phosphotransferase and thymidine kinase
cassettes are used for negative and positive selection,(I and J) Simultaneous immunohistochemical labeling of both endogenous Oct4 and EGFP in undifferentiated (I) and differentiated (J) cells confirms that EGFP
labeling is consistent with endogenous Oct 4 expression. The hOct4-EGFP reporter transgene delivered by ePiggyBac is therefore functional.
(K) Final optimization of transposition parameters: compared to basic gene delivery protocols (basic) inspired by published data (Siemen et al., 2005), expressing
the transposase from the CAG promoter, with 6 mg of DNA per 1.53 105 cells, a transposase/transposon ratio of 1:2 and transfection solution L (improved) led to
a significant increase in transgenesis efficiency.
(L) Different amounts of ePiggyBac transposase per nucleofection reaction allows control over the number of transposons integrated in the hESC genome.
Inset in EB photo shows embryoid body EGFP fluorescence level.
Scale bars represent 100 mm (A–D, H), 200 mm (I, J). Asterisks indicate significant difference (p < 0.01) between clone 16 and wtPiggyBac.ll Stem Cell 5, 332–342, September 4, 2009 ª2009 Elsevier Inc. 335
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Figure 2. ePiggyBac Retains Basic Properties of the Original
PiggyBac System
(A) Schematic representation of the plasmid rescue system used to sequence
and map integration sites. In addition to the EGFP-expressing cassette, the
transposon includes a DNA replication origin and an ampicillin selection
cassette. 62 integration sites were sequenced.
(B) Consensus logo analysis revealed no obvious consensus sequence other
than the TTAA tetranucleotide sequence required for PiggyBac transposition.
(C) Frequency plots revealed a preference for AT-rich regions around the site of
integration.
(D) ePiggyBac exhibited no hot spot for integration and all chromosomes of the
XX ESC line RUES2 were hit.
(E) Distribution of insertions within known transcription units revealed a prefer-
ence for introns over exons, a 10 Kbwindow upstream of the transcription start
site, and a 10 Kb window downstream of the poly(A) site.336 Cell Stem Cell 5, 332–342, September 4, 2009 ª2009 Elsevier Inrespectively (Figure 3A). This construct enabled us to test the
approach schematized in Figure 3B. For transgene integration,
the transposon is cotransfected with the ePiggyBac-expressing
vector. Transposon remobilization is expected to occur once or
several times until the helper plasmid is diluted by cell division
and transposase activity wears off. Once transposase activity
has disappeared, the transgene remains immobile on the
host genome. For transposon removal, binding of the Gal4-
ePiggyBac chimeric protein to the UAS-carrying recipient
plasmid increases the chances that the transposon is remobi-
lized from the host genome to the recipient plasmid (Maragatha-
vally et al., 2006). To test this strategy, we first used ePiggyBac
to create an RUES2 cell line containing a single copy of the RFP-
expressing transposon (Figure 3A) as determined by SplinkTA
PCR. This cell line was maintained under 200 mg/ml neomycin
selection for 5 passages to eliminate nontransgenic cells. It is
ganciclovir sensitive and exhibits uniform RFP expression
(Figure 3C).
Upon cotransfection of the Gal4-ePiggyBac helper and recip-
ient plasmid, 6.48% ± 1.04% colonies exhibited mosaic RFP
expression (Figure 3D), whereas mosaic RFP expression was
not observed in nontransfected cultures (not shown). DNA
extracted from these hESC was used to transform E. coli
bacteria. Bacterial transformants were then selected for both
ampicillin and kanamycin resistance conferred by the recipient
plasmid and transposon, respectively. Sequence analyses
revealed that the transposable element originally carried by the
transgenic hESC genome had been transferred to the recipient
plasmid (Figure 3E). In addition, presence of the typical TTAA
tetranucleotide at the junction between transposon and plasmid
sequences indicated that the transposon had been inserted in
the recipient plasmid by ePiggyBac transposition.
Ganciclovir selection was used to recover RFP-negative hESC
colonies. These colonies did not survive under neomycin
selection (not shown), indicating that the cells had lost all three
selectable markers: RFP, neomycin phosphotransferase, and
thymidine kinase. Importantly, untransfected RFP-hESCs or
controls where RFP-hESCs were transfected with either helper
or recipient plasmid alone did not give rise to ganciclovir-resis-
tant colonies (Figure 3F). This result indicates that re-expression
of the transposase alone is inefficient at removing transgenes
and that transgene removal is dependent on the Gal4 and UAS
components. This result also excludes the possibility that
ganciclovir resistance, neomycin sensitivity, and loss of RFP
expression are due to silencing of selection cassettes on the
transposon. Furthermore, SplinkTA PCR genotyping (Figure 3G)
indicated that ganciclovir-resistant/neomycin-sensitive/RFP-
negative colonies did not carry any transgene. Finally, we looked
for unequivocal evidence that transposon removal had occurred
without leaving footprint mutations in the genome by sequencing
transposon integration sites before and after excision. Compar-
isons of transposon integration site sequences before and after
excision revealed that transgene removal had occurred without
creation of footprint mutations and genomic sequences had
reverted to a wild-type state (Figure 3H). As of this writing,
mutation-free excisions have been performed in 32 independent
hESC clones, and althoughWang et al. (2008) have reported that
only 95% excisions are mutation free, we have not yet observed
mutations at the site of excision in hESCs. It is possible thatc.
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Figure 3. ePiggyBac Transposons Can Be Removed from the
Genome
(A) Schematic representation of the transgene integrated in hESC line RUES2.
The construct includes a pUC DNA replication origin for plasmid rescue,
neomycin/kanamycin phosphotransferase (Neo) and thymidine kinase (TK)
cassettes for negative and positive selections, respectively, and an RFP-
expressing insert using the PGK promoter and SV40 poly(A) (pA) signal.CeePiggyBac’s higher transposition efficiency in hESCs efficiency
allows for cleaner excision. In addition, karyotypic analysis of
20 metaphases indicated that transposon removal does not
compromise chromosomal integrity (Figure S6).
Overall, these data indicate that ePiggyBac can both deliver
large multicomponent transgenes to the hESC genome and
remove them without leaving any mutation.
ePiggyBac-Mediated Loss and Gain of Function Directs
hESC Differentiation toward Specific Cell Types without
Genome Alterations
We next investigated whether the ability to deliver large multi-
component transgenes to hESC and remove them could be
used to drive hESC differentiation toward a specific cell type.
We first created a transposable and inducible short hairpin
RNA (shRNA)-expressing system in order to knock downpluripo-
tency gene expression. This transposon (Figure 4A) expresses
shRNAs modeled after human miR-30 (Silva et al., 2005).
Previous studies have shown that miR-30-based shRNAs inhibit
gene expression more efficiently than simple stem-loop shRNAs
and their expression can be driven by Pol II promoters. This
(B) Schematic representation of the integration/removal approach. For
transgene integration, the transposon is cotransfected with the ePiggyBac-
expressing vector. Transposon remobilization is expected to occur once or
several times until the helper plasmid is diluted by cell division and transpo-
sase activity wears off. Once transposase activity has disappeared, the
transgene remains immobile on the host genome. For transposon removal,
we created a fusion between the Gal4 DNA binding domain (G4) and the
ePiggyBac transposase (ePBac). The R6Kg-UAS recipient plasmid includes
an ampicillin resistance cassette (Amp), 14 repeats of the UAS sequence,
and an R6KgDNA replication origin. Upon expression, the chimeric G4-ePBac
transposase binds to the UAS sequences, which is expected to increase
chances that transposons are transfered to the recipient plasmid. The R6Kg
DNA replication origin is active only in E. coli strains that provide the p protein
encoded by the pir gene. DH5a E. coli strains used in this study for plasmid
rescue are pir; therefore upon expression of Gal4-ePiggyBac and DNA
extraction from hESCs, the recipient plasmid can give rise to ampicillin-
resistant DH5a colonies only if a transposon containing a pUC replication
origin has been inserted in the recipient plasmid. In addition, the modified
plasmid resulting from integration of the transposon into the recipient plasmid
only contains one functional replication origin in DH5a strains. This reduces
possible replication defects and decreases in plasmid rescue efficiency result-
ing from interference between two replication origins in the same plasmid.
(C) After neomycin selection, an RFP-positive line containing a single copy of
the transgene was established.
(D) Upon transfection of the recipient plasmid (R6Kg-UAS) and Gal4-
ePiggyBac, helper colonies exhibit mosaic RFP expression.
Scale bar represents 100 mm.
(E) Analyses of six plasmid sequences from ampicillin/kanamycin resistant
E. coli clones reveal that the transposon originally carried by the hESC genome
(black sequence) has been inserted in the recipient plasmid (blue sequence) at
a TTAA junction typical of ePiggyBac transposition.
(F) Ganciclovir-resistant colonies are observed only after cotransfection of
both the Gal4-ePiggyBac helper and R6Kg-UAS recipient plasmid.
(G) PCR genotyping reveals that ganciclovir-resistant hESC lines (GanR-1 and
GanR-2) have reverted from a transgenic (RUES2-RFP) to a wild-type (RUES2)
RUES2 genotype. The lower band on the gel indicates nonmutated allele.
(H) DNA sequences of a transposon integration locus in nontransgenic cells
(RUES2), transgenic cells before transposon removal (RUES2-RFP), and
transgenic cells after transposon removal (Revertant). Sequence analyses
show that transgene (blue) removal did not leave any mutation in the RUES2
genome (green). The chromatogram confirms the absence of mutations in the
revertant sequence.ll Stem Cell 5, 332–342, September 4, 2009 ª2009 Elsevier Inc. 337
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Figure 4. ePiggyBac Transposons Can Deliver Doxycyclin-Inducible
shRNA-Expressing Cassettes to Induce hESC Differentiation
(A) Schematic representation of the shRNA-expressing transposable element.
The transgene includes a TetON cassette, a neomycin selection cassette
(Neo), an HS4 chicken insulator, and Tet-responsive elements (TRE) driving
shRNA expression (pA, poly(A) signal).
(B) Quantitative RT-PCR analyses show that 4 days after the addition of
doxycyclin (+DOX), the expression of pluripotency markers Oct4, Sox2, and
Nanog decreases whereas levels of differentiation markers Gata6, Sox1,
Brachyury, and Cdx2 increase compared to samples grown in the absence
of doxycyclin (DOX) or in cells expressing a control anti-EGFP shRNA
(shEGFP +DOX).
(C and D) Cells grown in the absence of doxycyclin, which formed tightly
packed colonies characteristic of undifferentiated hESCs (C), whereas cells
expressing the anti-Oct4 shRNA exhibited a flattenedmorphology reminiscent
of differentiated cells (D).338 Cell Stem Cell 5, 332–342, September 4, 2009 ª2009 Elsevier Inenabled the use of the TetON system and control gene knock-
down by addition of doxycyclin to the cell culture medium.
RUES2 cells were transfected with an shRNA vector targeting
Oct4 and grown in the presence of neomycin until 500- to
1000-cell colonies were obtained. Doxycyclin was then added
to the conditioned culture medium to induce anti-Oct4 shRNA
expression. RT-PCR analyses showed that 4 days after the addi-
tion of doxycyclin, the expression of pluripotency markers Oct4,
Sox2, and Nanog decreased whereas differentiation markers
Gata6, Sox1, Brachyury, and Cdx2 increased compared to
samples grown in the absence of doxycyclin or in cells express-
ing a control anti-EGFP shRNA (Figure 4B; Figure S7A). Concom-
itantly, clear morphological differences appeared between cells
grown in the absence of doxycyclin, which formed tightly packed
colonies (Figure 4C) characteristic of undifferentiated hESCs,
and cells expressing the anti-Oct4 shRNA, which exhibited a flat-
tened morphology reminiscent of differentiated cells (Figure 4D).
These morphological changes were accompanied by a strong
increase in immunoreactivity for the trophectodermmarker cyto-
keratin 18 in filamentous structures characteristic of epithelial
cell types (Figure 4E; Figure S7). These results indicate that
the ePiggyBac system can be used to deliver loss-of-function
vectors that trigger hESC differentiation in a doxycyclin-
inducible manner despite the presence of nondifferentiating
culture conditions.
We next investigated whether a combination of loss- and gain-
of-function systems could be used to drive differentiation toward
one particular cell type, namely a neural cell type. We added
a thymidine kinase cassette to our TetON system (Figure 4A)
and first transfected RUES2 cells with a gain-of-function
construct expressing human Sox1 cDNA to direct differentiation
toward neuroectoderm (not shown). We noticed that in condi-
tioned medium, overexpression of Sox1 alone does not direct
differentiation toward neuroectoderm (not shown), possibly
because it cannot counteract FGF and activin/nodal signaling
activated by conditionedmedium tomaintain hESC self-renewal.
Therefore, we cotransfected the Sox1 gain-of-function construct
together with loss-of-function constructs expressing shRNAs
against Oct4, Gata6, Sox 17, Brachyury, or Cdx2 (1 mg of each
construct per nucleofection reaction) to induce differentiation
but minimize the acquisition of endodermal, mesodermal, or
trophectodermal phenotypes. In preliminary experiments, we
tested that each individual shRNA was able to knock down its
target gene (Figure S8). Upon delivery of the transgene cocktail,
500- to 1000-cell transgenic colonies were obtained under
neomycin selection before doxycyclin was added to the condi-
tioned culture medium. After 10 days of doxycyclin treatment,
expression levels of pluripotency markers decreased signifi-
cantly and expression of endogenous neural-specific genes
Sox1 and NFH became preponderant over that of endodermal,
mesodermal, and trophectodermal markers (Figure 5A). Further-
more, hESCs differentiated into flattened cell types, and groups
of 10–50 round structures (Figure 5B) reminiscent of structures
defined by others as neural rosettes (Zhang et al., 2001) had
(E) These morphological changes were accompanied by a loss in Oct4 immu-
noreactivity and a strong increase in immunoreactivity for the trophectoderm
marker cytokeratin 18.
Scale bars represent 30 mm (C and D), 50 mm (E).c.
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Figure 5. ePiggyBac Transposons Can Direct hESC Differentiation
toward a Neural Phenotype and Be Removed
(A) Quantitative RT-PCR analyses indicate that in hESCs transfected with
a cocktail of gain- and loss-of-function transposons, expression of pluripo-
tency markers significantly decrease upon doxycyclin treatment and the
expression of neuroectodermal marker Pax6 and neural-specific genes
Sox1 and NFH is preponderant over that of endodermal (Mixl1, Sox17), meso-
dermal (Chordin), and trophectodermal (hCG beta) markers.Celappeared in 91% (n = 309) of flattened cell colonies. Immunoflu-
orescent staining for the neuroectodermal marker Pax6 and the
neural precursor marker nestin (Figure 5C) confirmed that the
round structures were neural rosettes (Zhang et al., 2001). These
results indicate that ePiggyBac can deliver cocktails of doxycy-
clin-inducible loss- and gain-of-function transgenes that drive
differentiation toward a neuronal cell type without the need for
a defined culture medium (other than the conditioned medium
commonly used to maintain hESCs), feeder cells, or embryoid
body formation (Zhang et al., 2001).
We finally asked whether transgenes could be removed
without loss of the neural phenotype. We isolated neural rosettes
by enzymatic treatment and let them form neural spheres (Zhang
et al., 2001) in conditioned medium supplemented with doxycy-
clin. Seven-day-old neural spheres were then triturated to obtain
5- to 10-cell clumps, nucleofected with the Gal4-ePiggyBac
helper and UAS-carrying recipient plasmid, and cultured in
suspension in N2 medium. 48 hr after transfection, ganciclovir
selection was applied and ganciclovir-resistant neural spheres
were obtained after an additional 7 days of culture (Figure 5D).
Neural spheres were then cut in halves. One half of the sphere
was plated on matrigel-coated plates and cultured for 4 days.
Upon attachment to the matrigel substrate, they formed neurites
expressing the neural precursor marker nestin and the neuronal
markers doublecortin, neurofilament heavy chain, and Map2
(Figures 5E–5G). PCR genotyping was performed on the other
half of the neural sphere to confirm that the transgenes had
been removed (Figure 5H). Interestingly, neural spheres origi-
nating from a clone containing all six transposons were devoid
of transgenes after ganciclovir selection. These results indicate
that ePiggyBac can deliver cocktails of transgenes that direct
differentiation toward a specific phenotype, which is conserved
upon transgene removal.
DISCUSSION
Most, if not all, gene delivery systems fall into two categories:
systems that mediate irreversible gene integrations (e.g., viral
vectors, PhiC31-based systems, plasmids, and BACs) and
systems that can be excised but leave mutations in the host
genome upon excision (e.g., Cre-, Flp-, or Sleeping beauty-
based systems). These irreversible genetic alterations could
potentially lead to higher predisposition toward uncontrolled
cellular behavior and they constitute a significant barrier to clin-
ical applications of hESCs. ePiggyBacminimizes these concerns
by enabling fully reversible gene delivery.
(B and C) Neural rosettes exhibiting Pax6 and Nestin immunoreactivity also
appear in doxycyclin-treated cultures.
(D) Upon transgene removal, ganciclovir-resistant neural spheres are selected.
(E–G) These neural spheres give rise to nestin- (E), doublecortin (DCX)-, NFH-
(F), and Map2-positive (G) neurons.
(H) PCR genotyping on ten different samples confirms that ganciclovir-resis-
tant neural spheres are devoid of transposons. Transposon-specific primers
that detect the inverted repeats of ePiggyBac were used to demonstrate
that regardless of number of insertions. all transgenes were removed. Primers
detecting endogenous Sox1 genomic sequences were used as positive
controls (Endo Sox1). Neg., indicates the genotype of the parent neural sphere
where transgenes have not been removed.
Scale bars represent 50 mm (B), 5mm(C), 100 mm (D), 20mm (EandG), 10mm (F).l Stem Cell 5, 332–342, September 4, 2009 ª2009 Elsevier Inc. 339
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ePiggyBacThe present data show that in ES cells, ePiggyBac’s efficiency
is not only superior to that of viral vectors, it is also superior to
that of previously described transposases, including other Pig-
gyBac-based systems (Cadinanos and Bradley, 2007; Yusa
et al., 2009; Woltjen et al., 2009; Kaji et al., 2009). In addition,
the efficiency of ePiggyBac is conserved between human,
nonhuman primate, and rodent ES cells. Our data show that
ePiggyBac can deliver inserts of up to 18 Kb, which enables the
use of large promoters for cell-specific transgene expression.
Transgenes need not be active in undifferentiated hESCs to
permit the selection of transgenic cells because in addition to
a reportersystem,ePiggyBactransposonscan includeaselection
cassette regulated by a separate promoter. Therefore, in vivo
labeling of specific cell types arising from transgenic hESC differ-
entiation is now straightforward. This should greatly facilitate the
isolation and purification of cell populations of medical interest.
The ability to use multiple expression cassettes also permits
the design of conditional loss- and gain-of-function strategies
to direct hESC differentiation toward cell types that can be
used for drug screens, toxicological assays, or basic research
on human diseases. In addition, the possibility to remove trans-
genes from the hESC genome without leaving any mutation at
the site of insertion eliminates risks associated with irreversible
gene delivery approaches. Differentiation via gain- and loss-of-
function cassettes also reduces the need for defined media
formulation. Ultimately, this should facilitate the generation of
clinical-grade hESC derivatives by reducing the need for
animal-derived media components and feeders.
EXPERIMENTAL PROCEDURES
DNA Constructs
The original PiggyBac transposase DNA was obtained from Dr. M. Fraser
(University of Notre Dame, IN). The ePiggyBac transposase cDNA was custom
synthesized by Integrated DNA Technologies. To generate helper plasmids,
transposase cDNAs were cloned in pBluescript (Stratagene) downstream of
a human phosphoglycerate kinase (PGK) or CAG promoter and upstream of
an SV40 polyadenylation signal sequence. Minimal 313 bp 50TR and 235 bp
30TR were custom synthesized and cloned upstream and downstream,
respectively, of expression cassettes containing the PGK promoter driving
EGFP (BD Biosciences) or tagRFP (Evrogen). The plasmid rescue system
also included an ampicillin resistance cassette and an origin of replication
from pBluescript cloned between the 50- and 30-terminal repeats. To improve
gene transfer efficiency, mutations in terminal repeats were introduced with
the GeneMorph II random PCRmutagenesis system (Stratagene). To generate
the Oct4-EGFP transposon, the human Oct4 promoter (Gerrard et al., 2005)
was cloned upstream of EGFP. The 250 bp chicken b-globin HS4 core insu-
lator (Recillas-Targa et al., 2002) was custom synthesized and inserted
between the hOct4-EGFP reporter and a neomycin/kanamycin cassette
subcloned from pEGFP-N1 (BD Biosciences). Finally, the hOct4-EGFP
reporter, HS4 insulator, and selection cassette were flanked by 50 and 30TR.
The helper plasmid for transgene removal was generated by cloning the
Gal4 DNA binding domain between the PGK promoter and the transposase
cDNA of the ePiggyBac helper plasmid to create a Gal4-ePiggyBac fusion.
Two consensus nuclear localization signals (MPKKKRKVDPKKKRKVD) were
incorporated at the N terminus of the Gal4 DNA binding domain, and a flexible
linker (GGSGGSGSS) was incorporated at its C terminus. The recipient
plasmid was generated by adding 14 UAS sequences to the pLD53 backbone
(Metcalf et al., 1996). This plasmid contains an R6Kg origin of replication,
which is inactive unless the p protein is provided by the bacterial host. It
was therefore maintained in pir-2 E. coli (Invitrogen). For nucleofection, all
plasmids were prepared with a Qiaprep Spin Miniprep kit (QIAGEN) and
purified by phenol:chloroform extraction and ethanol precipitation. For RNA340 Cell Stem Cell 5, 332–342, September 4, 2009 ª2009 Elsevier Ininterference, shRNA were designed as described (Silva et al., 2005). shRNAs
used in this study are summarized in Table S1.
hESC Lines and Culture Conditions
hESC lines: RUES1 (James et al., 2006), RUES2, H1 (Thomson et al., 1998),
HUES10 (Cowan et al., 2004), and BGN1 (Mitalipova et al., 2003), as well as
Macacca fascicularis, M. nemestrina (both from the Reproductive Biology
Core, Washington National Primate Research Center), and M. mulatta line
R366.4 (Thomson et al., 1995). ESCs were grown on mitotically inactivated
MEF feeders (strain CF-1, Chemicon) in HUESM (DMEM supplemented with
20%KSR, 100 mMnonessential amino acids, 2 mMGlutaMAX, 100 mM b-mer-
captoethanol, 100 U/ml penicillin, 100 mg/ml streptomycin, and 13 B27
supplement without Vitamin A; all from Invitrogen) supplemented with 20 ng/
ml bFGF. All hESC lines were transferred to feeder-free conditions on Matri-
gel-coated dishes and cultured in conditioned medium (CM) for at least one
passage prior to gene delivery. For the preparation of CM, mitotically inacti-
vated MEFs were seeded at a density of 4 3 106 cell per 100 mm dish and
incubated in HUESM supplemented with 20 ng/ml bFGF for 24 hr. CM was
then collected, supplemented with 20 ng/ml bFGF, and used to feed human
and macacca ESCs. For expansion, hESC were enzymatically passaged
with 1 mg/ml dispase treatment (James et al., 2006). Embryoid bodies were
generated by incubation of hESC cultures in dispase until colonies detached
from the substrate. Individual aggregates were then transferred to low attach-
ment 96-well plates (Evergreen) and grown in HUESM for at least 2 weeks prior
to GFP or immunofluorescence imaging. To generate teratomas, 1–2 3 106
hESCs were injected into the rear leg muscle or subcutaneously into SCID/
Beige mice. Teratomas were allowed to develop for 6–8 weeks, excised, fixed
in neutral buffered formalin, and analyzed histologically by trained patholo-
gists. hESC lines were karyotyped by standard G-banding.
Gene Transfer
Prior to dissociation and nucleofection, hESC and Macacca ESC cultures or
dissociated neural spheres were treated for 1 hr with 10 mM ROCK inhibitor
Y-27632 which strongly diminishes dissociation-induced apoptosis and
increases cloning efficiency (Watanabe et al., 2007). ESCs were then dissoci-
ated in 0.25% (wt/vol) trypsin-EDTA at 37C for 5 min, washed in CM with
ROCK inhibitor, and resuspended in nucleofection solution V or L (Amaxa).
Helper and transposon plasmids were added to the cell suspension, and
nucleofection was performed with program setting B-016 as described
(Siemen et al., 2005). ESCs were then plated in CM supplemented with
10 mM ROCK inhibitor at densities of 23 105 cells per 6 cm dish for the selec-
tion of clonal cell line hOct4-EGFP or 23 103 cells per 6 cm dish for fluorescent
colony counts. Culture medium was changed to CM without ROCK inhibitor
20–24 hr after nucleofection and colonies were allowed to form for 7 days
before numbers of fluorescent colonies were evaluated. EGFP-positive colony
count based onmicroscopic observation was preferred over single-cell counts
by flow cytometry. This constitutes a more stringent and more functionally
relevant way to assess the efficiency of a gene delivery system because trans-
gene silencing is frequent in hESCs and only a fraction of single transgenic
cells gives rise to an EGFP-labeled marked cell line that can be used for further
applications (Braam et al., 2008). In experiments where selection was needed,
exposure to neomycin (100 mg/ml) or ganciclovir (1 mM) was initiated 3 days
after nucleofection and maintained until large resistant colonies became
visible. Media were refreshed daily.
Plasmid Rescue and hESC Genotyping
Genomic DNA isolated from transgenic hESC clones was digested with
restriction enzymes BamHI, BglII, and NotI. DNA was self-ligated at low
concentration with T4 DNA ligase overnight at 16C, precipitated with 100%
isopropanol, and washed with 70% ethanol before transformation in DH10B
Escherichia coli and selection on ampicillin. For transgene removal experi-
ments, undigested DNA was extracted from hESC cultures and used for
E. coli transformations. Bacterial transformants were then selected on both
ampicillin and kanamycin. Plasmid DNA from resistant E. coli clones was
sequenced with primers that read through the 50TR of the PiggyBac trans-
poson. Number of insertions were determined as described (Yin and Largaes-
pada, 2007) by SplinkTA PCR, which usually provides a higher resolution than
Southern blots. hESCs were genotyped before and after transposon removalc.
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ePiggyBacwith the following primers: 30TR-F 50-CTTAAGGAATTCGATAAAAG-30 and
30TR-R 50-GATACATTGATGAGTTTGG-30, which read through the 30TR of
the PiggyBac transposon, and 18-F 50-CGTGCTTACAGGCATTGAGC-30 and
18-R 50-CTGGAACCTCGACTTCTTGG-30, which flank the integration site of
the Neo-TK-RFP transposon (Figure 3A) on chromosome 18. Neural spheres
were genotyped with transposon-specific primers (forward 50-CTCTAGAT
CATAATCAGCC-30, reverse 50-ACGCCTTAAGATACATTGATGAG-30 ), and
primers detecting endogenous Sox1 genomic sequences (forward 50-GAG
ATTCATCTCAGGATTGAGATTC-30, reverse 50-CGAGCGCAATGGCAGATTT
AC-30) were used as positive controls.
mRNA Quantifications
RNA was isolated with RNA-Bee (Tel-Test Inc. Friendswood, TX) and first-
strand cDNAwas generated with a SuperScript III cDNA First Strand Synthesis
kit (Invitrogen). Quantitative real-time PCR reactions were performed with
a LightCycler 480 SYBR Green I Master Kit (Roche). Primers used to measure
mRNA levels are summarized in Table S2.
Immunohistochemical Assays and Confocal Imaging
Undifferentiated hESCs or adherent embryoid bodies plated on Matrigel-
coated MatTek coverslip dishes were fixed in 4% paraformaldehyde (PFA),
washed in phosphate-buffered saline solution, and blocked in 0.1% Triton
X-100 and 3% donkey serum in PBS. Samples were exposed to primary anti-
bodies in blocking solution overnight at 4C, washed 3 times in PBS with 0.1%
tween-20 at room temperature, and exposed to Alexa-conjugated secondary
antibodies (dilution 1:500). Primary antibodies included Oct3/4 (Signal Trans-
duction Labs), tagRFP (Evrogen), GATA6, Nestin, Cytokeratin 18, and double-
cortin (Santa Cruz), Muscle MHC/MF20 (Developmental Studies Hybridoma
Bank), Neurofilament Heavy Chain (SMI32, Sternberger), Map2 (Millipore)
Nanog, and Sox2 (R&D Systems). Alexa-conjugated secondary antibodies
and SytoxOrange nuclear counterstain were purchased from Molecular
Probes. All imaging was performed on a Zeiss LSM 500 Pascal confocal
microscope.
Flow Cytometry
Prior to dissociation and analysis, hESCwere treated for 1 hr with 10 mMROCK
inhibitor Y-27632 to minimize cell death. Cells were then dissociated in 0.25%
(wt/vol) trypsin-EDTA at 37C for 5 min, washed in CM with ROCK inhibitor,
and resuspended in ice-cold PBS supplemented with 0.1% BSA and
0.5 mM EDTA. Live cell analyses were then performed immediately with a
BD LSRII-2 and DiVa 5.0.2 software (Becton Dickinson).
Statistical Analysis
The statistical significance (p values) in means of two-sample comparison was
determined with Student’s t test (Microsoft Excel). The statistical significance
in mean values among multiple sample groups was examined with two-way
ANOVA and Bonferroni’s post-hoc test. Values shown in graphs represent
the mean ± SD.
SUPPLEMENTAL DATA
Supplemental Data include ten figures and two tables and can be found
with this article online at http://www.cell.com/cell-stem-cell/supplemental/
S1934-5909(09)00347-6.
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